Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 30, 2026Reported sale · Form 4Johannes Jacob Pieter Kastelein, Chief Scientific Officer · $1.3MOpen the filing ↗
- Sep 29, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- Sep 21, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record38920 flagged findings
Reported transactions (Form 4)80since Jul 16, 2025 · and 32 other holdings
Corporate events (8-K)14since Jan 8, 2024
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-07share offering or dilution eventrecentOpen filing ↗“…we are not yet profitable and have incurred losses in each annual period since our inception. As of March 31, 2026, we had an…”
+1 more passage from the same document
- “…liabilities consisted of the following: (in thousands of USD) March 31, 2026 December 31, 2025 Accrued research and development…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 389)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 2, 26Form 4 ↗Insider transaction
- Sep 29, 268-K ↗Current report · Other events
- Sep 22, 26SCHEDULE 13D/A ↗Stake with intent to influence · Frazier Life Sciences Public Fund, L.P. · 8.7% · event on Sep 18, 26 · amendment
- Sep 21, 268-K ↗Current report · Other events
- Aug 25, 26Form 144/A ↗Notice of proposed sale · amendment
- Aug 25, 26Form 4 ↗Insider transaction
- Aug 24, 26Form 144 ↗Notice of proposed sale
- Aug 14, 268-K/A ↗Current report · A senior executive left or was appointed · amendment
- Aug 14, 26Form 3 ↗Insider transaction
- Aug 14, 268-K ↗Current report · A senior executive left or was appointed
- Aug 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 8.8% · event on Jun 30, 26 · amendment
- Aug 5, 268-K ↗Current report · Results
- Aug 5, 2610-Q ↗Quarterly report
- Jul 24, 268-K ↗Current report · Other events
- Jul 22, 268-K ↗Current report · A senior executive left or was appointed
- Jun 4, 26SCHEDULE 13G/A ↗Passive stake · Capital World Investors · 10.4% · event on May 29, 26 · amendment
- Jun 3, 268-K ↗Current report · A senior executive left or was appointed
- May 27, 26Form 4 ↗Insider transaction
- May 26, 26Form 144 ↗Notice of proposed sale
- May 14, 26SCHEDULE 13D/A ↗Stake with intent to influence · BCLS Fund III Investments, LP · 1.8% · event on May 12, 26 · amendment
389 filings on record, the oldest from Aug 4, 22.
Listing the 25 most recent filings of the 389 on record.
1310
5 senior executive changes2026show all 5hide
- Aug 14, 26A senior executive left or was appointed8-K/A 5.02 ↗
- Aug 14, 26A senior executive left or was appointed8-K 5.02 ↗
- Jul 22, 26A senior executive left or was appointed8-K 5.02 ↗
- Jun 3, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 24, 26A senior executive left or was appointed8-K 5.02 ↗
- Aug 15, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Jul 11, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 17, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Dec 13, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Oct 18, 24Past accounts declared unreliable and being restated8-K 4.02 ↗
- Jul 18, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 1, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Feb 15, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jan 8, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Frazier Life Sciences Public Fund, L.P.8.7%Sep 18, 26SCHEDULE 13D/A ↗15 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- ForGrowth NAP B.V.8.3%Sep 26, 25SCHEDULE 13D/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Frazier Life Sciences X, L.P.6.5%Aug 18, 25SCHEDULE 13D/A ↗21 co-filers on this document — the figure is the largest single stake, not their sum.
- BCLS Fund III Investments, LP1.8%May 12, 26SCHEDULE 13D/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Capital World Investors10.4%May 29, 26SCHEDULE 13G/A ↗3 earlier filings
- RA Capital Management, L.P.9.9%Mar 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- FMR LLC8.8%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- VIKING GLOBAL INVESTORS LP3.7%Dec 31, 25SCHEDULE 13G/A ↗11 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Aug 24, Kastelein Johannes Jacob Pieter filed notice of intent to sell up to $7.0M. That is about 0.21% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $1.3M on Sep 30, per their Form 4. That is 20% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+1 more recent notices · 1 with a later sale
- Sep 30, 26Sell$1.3MJohannes Jacob Pieter KasteleinChief Scientific Officer↗
- Sep 14, 26Buy$227KMichael H. DavidsonChief Executive Officer↗
- Sep 4, 26Sell$41KJohn W Smither↗
- Aug 24, 26Sell$3.4MJohannes Jacob Pieter KasteleinChief Scientific Officer↗
- Jul 20, 26Sell$2.1MLouise Frederika KooijChief Accounting Officer↗
- Jul 20, 26Sell$990KLouise Frederika KooijChief Accounting Officer↗
- Jul 20, 26Sell$92KLouise Frederika KooijChief Accounting Officer↗
- Jun 22, 26Sell$1.2MLouise Frederika KooijChief Accounting Officer↗
- Jun 22, 26Sell$9KLouise Frederika KooijChief Accounting Officer↗
- May 26, 26Sell$2.3MLouise Frederika KooijChief Accounting Officer↗
- Mar 11, 26Sell$1.3MLOUIS G LANGE↗
- Mar 11, 26Sell$14KLOUIS G LANGE↗
There are 11 more transactions in this stretch.
Stock compensation, tax and giftsshow the 17 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 30, 26Compensationamount n/aJohannes Jacob Pieter KasteleinChief Scientific Officer↗
- Sep 1, 26Compensationamount n/aRobert William GunningVice President, Controller↗
- Aug 24, 26Compensationamount n/aJohannes Jacob Pieter KasteleinChief Scientific Officer↗
- Jul 20, 26Compensation$298KLouise Frederika KooijChief Accounting Officer↗
- Jul 20, 26Compensation$894KLouise Frederika KooijChief Accounting Officer↗
- Jun 22, 26Compensation$273KLouise Frederika KooijChief Accounting Officer↗
- Jun 22, 26Compensation$179KLouise Frederika KooijChief Accounting Officer↗
- May 26, 26Compensation$600KLouise Frederika KooijChief Accounting Officer↗
- May 26, 26Compensation$55KLouise Frederika KooijChief Accounting Officer↗
- Mar 9, 26Compensationamount n/aJohannes Jacob Pieter KasteleinChief Scientific Officer↗
- Mar 9, 26Other$513KLOUIS G LANGE↗
- Mar 6, 26Compensationamount n/aJohannes Jacob Pieter KasteleinChief Scientific Officer↗
- Mar 5, 26Compensationamount n/aJohannes Jacob Pieter KasteleinChief Scientific Officer↗
- Mar 2, 26Compensationamount n/aMichael H. DavidsonChief Executive Officer↗
- Feb 26, 26Compensationamount n/aMichael H. DavidsonChief Executive Officer↗
- Feb 25, 26Compensationamount n/aMichael H. DavidsonChief Executive Officer↗
- Feb 24, 26Compensationamount n/aMichael H. DavidsonChief Executive Officer↗
The full record holds 200 transactions and goes back to Dec 29, 23.
Its sector and its market
NewAmsterdam Pharma Co. N.V. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From NewAmsterdam Pharma Co. N.V., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow NewAmsterdam Pharma Co. N.V. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 389 documents on file, from Aug 4, 2022 to Oct 2, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.